Our top pick for
Building a portfolio
Reata Pharmaceuticals, Inc is a biotechnology business based in the US. Reata Pharmaceuticals shares (RETA) are listed on the NASDAQ and all prices are listed in US Dollars. Reata Pharmaceuticals employs 261 staff and has a trailing 12-month revenue of around USD$9 million.
|52-week range||USD$88.17 - USD$186.817|
|50-day moving average||USD$115.0446|
|200-day moving average||USD$122.081|
|Wall St. target price||USD$243.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.056|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$9 million|
|Gross profit TTM||USD$-150,061,000|
|Return on assets TTM||-18.37%|
|Return on equity TTM||-73.49%|
|Market capitalisation||USD$3.5 billion|
TTM: trailing 12 months
There are currently 3.5 million Reata Pharmaceuticals shares held short by investors – that's known as Reata Pharmaceuticals's "short interest". This figure is 4.6% up from 3.3 million last month.
There are a few different ways that this level of interest in shorting Reata Pharmaceuticals shares can be evaluated.
Reata Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Reata Pharmaceuticals shares currently shorted divided by the average quantity of Reata Pharmaceuticals shares traded daily (recently around 276888.56). Reata Pharmaceuticals's SIR currently stands at 12.5. In other words for every 100,000 Reata Pharmaceuticals shares traded daily on the market, roughly 12500 shares are currently held short.
However Reata Pharmaceuticals's short interest can also be evaluated against the total number of Reata Pharmaceuticals shares, or, against the total number of tradable Reata Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Reata Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Reata Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1459% of the tradable shares (for every 100,000 tradable Reata Pharmaceuticals shares, roughly 146 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Reata Pharmaceuticals.
Find out more about how you can short Reata Pharmaceuticals stock.
We're not expecting Reata Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Reata Pharmaceuticals's shares have ranged in value from as little as $88.17 up to $186.817. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Reata Pharmaceuticals's is 1.539. This would suggest that Reata Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.